Related Experiment Videos
Myelography wiht perfluoroctylbromide. Comparison with Pantopaque
Investigative Radiology
|July 1, 1976
Summary
Perfluoroctylbromide is a promising, low-toxicity contrast agent for myelography, offering good radiopacity for subarachnoid imaging in dogs. Further study may be needed regarding its long retention in the intrathecal space.
Area of Science:
- Radiology
- Toxicology
- Veterinary Medicine
Background:
- Myelography requires effective and safe contrast media for diagnosing subarachnoid space abnormalities.
- Current contrast agents like Pantopaque may cause irritation and have limitations.
Purpose of the Study:
- To evaluate the efficacy and toxicity of perfluoroctylbromide as a contrast medium for intrathecal use in dogs.
Main Methods:
- Dogs were administered varying doses of perfluoroctylbromide intrathecally.
- Efficacy was assessed by radiopacity and diagnostic quality.
- Toxicity was evaluated through clinical signs, histological studies, and cerebrospinal fluid (CSF) analysis.
Main Results:
- Perfluoroctylbromide demonstrated free movement within the intrathecal space and provided satisfactory radiopacity.
- Dogs tolerated doses of 0.5-1.0 ml/kg without observable toxic manifestations.
- Histological findings and CSF analyses indicated significantly less irritation compared to Pantopaque.
Conclusions:
- Perfluoroctylbromide exhibits a favorable safety profile and diagnostic utility for myelography in canine models.
- Its low toxicity and good radiopacity make it a promising alternative contrast agent.
- Consideration for perfluorocarbon removal may be necessary due to its long retention time.